TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3073869

Group type: EXPERIMENTAL
Intervention: 5 MU/m2 human lymphoblastoid interferon (Wellferon), three times weekly for 6 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 25
Study: 29065815

Group type: EXPERIMENTAL
Intervention: Bio-oxidative ozone therapy (OG, n = 20)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Occlusal splints (OCSG, n = 20)
Number of subjects: 40
Study: 29026111

Group type: EXPERIMENTAL
Intervention: Distraction
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Expressive Suppression
Number of subjects: 16
Study: 26900599

Group type: EXPERIMENTAL
Intervention: SunProtect™ program with text message reminders
Number of subjects: 170

Group type: COMPARATOR
Intervention: Usual education (Control)
Number of subjects: 170
Study: 24433640

Group type: EXPERIMENTAL
Intervention: Gadobutrol (0.15 mmol/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Gd-DTPA (0.2 mmol/kg)
Number of subjects: 12
Study: 21830011

Group type: EXPERIMENTAL
Intervention: Laminaria tent (3 mm intracervical)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Misoprostol (400 μg vaginal)
Number of subjects: 70
Study: 19996929

Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted endothelial keratoplasty (FLEK)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Penetrating keratoplasty (PK)
Number of subjects: 80
Study: 17476291

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS)
Number of subjects: 8243
Study: 15699480

Group type: EXPERIMENTAL
Intervention: Dalteparin
Number of subjects: 602

Group type: COMPARATOR
Intervention: Coumarin derivative
Number of subjects: 602

Group type: EXPERIMENTAL
Intervention: Dalteparin vs Coumarin derivatives
Number of subjects: 602
Study: 11981594

Group type: EXPERIMENTAL
Intervention: 100 mg/day sertraline
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 100 mg/day sertraline plus 30 mg/day mianserin
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: 200 mg/day sertraline
Number of subjects: 295
Study: 9549822

Group type: EXPERIMENTAL
Intervention: Longitudinal quality of life measurements
Number of subjects: 0
Study: 7876651

Group type: EXPERIMENTAL
Intervention: Two injections on day 0
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: One injection on day 0 and 14
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: One injection on day 0 and 30
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: One injection on day 0 and 180
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Third dose on day 380
Number of subjects: 276
Study: 2197845

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous infusion of 400 micrograms octreotide per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 20
Study: 881256

Group type: EXPERIMENTAL
Intervention: Proplast-coated Thompson prosthesis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Cemented Thompson prosthesis
Number of subjects: 20
Study: 31129874

Group type: EXPERIMENTAL
Intervention: Preventive and interceptive orthodontic treatment needs (P&I Tx need) as assessed by the Index for Preventive and Interceptive Orthodontic Needs (IPION)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Characteristics associated with P&I Tx need
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: IPION scores in the definite treatment need group
Number of subjects: 202
Study: 27554812

Group type: EXPERIMENTAL
Intervention: Daily pasteurized raw whole egg powder
Number of subjects: 820

Group type: COMPARATOR
Intervention: Color-matched rice powder (control)
Number of subjects: 820
Study: 25772960

Group type: EXPERIMENTAL
Intervention: Intravenous iron sucrose (divided doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Total daily intake of Low Molecular Weight (LMW) iron dextran
Number of subjects: 0
Study: 24012983

Group type: EXPERIMENTAL
Intervention: Aspiration therapy plus lifestyle therapy (n=11)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Lifestyle therapy only (n=7)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Aspiration therapy (n=10 who completed additional year)
Number of subjects: 18
Study: 21248213

Group type: EXPERIMENTAL
Intervention: Locking intramedullary nail
Number of subjects: 51

Group type: COMPARATOR
Intervention: Locking plate
Number of subjects: 51
Study: 18957269

Group type: COMPARATOR
Intervention: Tension-free vaginal tape (TVT)
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Inside-out transobturator tape (TVT-O)
Number of subjects: 315
Study: 17296184

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 50

Group type: COMPARATOR
Intervention: Clinical touch transfers
Number of subjects: 50
Study: 15101486

Group type: EXPERIMENTAL
Intervention: Injection of 10 milliliters of lidocaine around the drain tube during removal
Number of subjects: 2

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 2
Study: 11794171

Group type: EXPERIMENTAL
Intervention: Sperm concentration < 13.5 x 10(6) per milliliter; motility < 32%; morphology < 9%
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Sperm concentration > 48.0 x 10(6) per milliliter; motility > 63%; morphology > 12%
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Percentage of sperm with normal morphologic features
Number of subjects: 1461

Group type: EXPERIMENTAL
Intervention: Sperm measurements overall
Number of subjects: 1461
Study: 9575014

Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Fluoxetine and Placebo
Number of subjects: 118
Study: 7512583

Group type: EXPERIMENTAL
Intervention: Topical retinoid AGN 190168
Number of subjects: 9

Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 9
Study: 3351688

Group type: EXPERIMENTAL
Intervention: Tracheal suctioning under direct vision at birth (group I)
Number of subjects: 572

Group type: COMPARATOR
Intervention: No tracheal suctioning (group II)
Number of subjects: 572
Study: 31520370

Group type: EXPERIMENTAL
Intervention: Concomitant therapy (pantoprazole 80 mg, amoxicillin 2000 mg, clarithromycin 1000 mg, and metronidazole 1000 mg daily in divided doses for 14 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Triple therapy (pantoprazole 80 mg, amoxicillin 2000 mg, and clarithromycin 1000 mg daily in divided doses for 14 days)
Number of subjects: 0
Study: 29114833

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg) and acetaminophen (1000 mg)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Oxycodone (5 mg) and acetaminophen (325 mg)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Hydrocodone (5 mg) and acetaminophen (300 mg)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: Codeine (30 mg) and acetaminophen (300 mg)
Number of subjects: 416

Group type: COMPARATOR
Intervention: Comparison of oxycodone and acetaminophen vs hydrocodone and acetaminophen
Number of subjects: 416
Study: 25628280

Group type: EXPERIMENTAL
Intervention: Cementless Oxford UKA
Number of subjects: 43

Group type: COMPARATOR
Intervention: Cemented Oxford UKA
Number of subjects: 43
Study: 23711446

Group type: EXPERIMENTAL
Intervention: Aerobic Interval Training (AIT) - 12-week program, 3 sessions per week at 85-90% of peakVO2 and 90-95% of peak heart rate
Number of subjects: 200

Group type: COMPARATOR
Intervention: Moderate Continuous Training (MCT) - 12-week program, 3 sessions per week at 60-70% of peakVO2 and 65-75% of peak heart rate
Number of subjects: 200
Study: 20933047

Group type: EXPERIMENTAL
Intervention: One-step self-etch adhesive (Xeno III; Dentsply/DeTrey)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Two-step etch-and-rinse adhesive (Exite; Ivoclar Vivadent)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Overall comparison of annual failure rates
Number of subjects: 78
Study: 19213790

Group type: EXPERIMENTAL
Intervention: High microvessel density (MVD) in multimodality-treated stage IIIA patients receiving tumor resection with negative margins (R0)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Low microvessel density (MVD) in multimodality-treated stage IIIA patients receiving tumor resection with negative margins (R0)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Stage IIIA patients
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Adenocarcinoma subtype
Number of subjects: 142
Study: 16933146

Group type: EXPERIMENTAL
Intervention: Training on work readiness program (3-week intensive training)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Advice on job placement by social workers (Control group)
Number of subjects: 64
Study: 15507095

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SIT) with tree pollen (birch)
Number of subjects: 27

Group type: COMPARATOR
Intervention: No intervention (Control group)
Number of subjects: 27
Study: 11698325

Group type: EXPERIMENTAL
Intervention: Hypercapnia (PaCO(2)=44 mmHg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Normocapnia (PaCO(2)=38 mmHg)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Hypocapnia (PaCO(2)=30 mmHg)
Number of subjects: 21
Study: 9513073

Group type: EXPERIMENTAL
Intervention: Zolpidem, 10 mg, administered continuously
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Zolpidem, 10 mg, administered intermittently (five nights zolpidem, two consecutive nights placebo per week)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control (placebo for two nights per week)
Number of subjects: 160
Study: 8062354

Group type: EXPERIMENTAL
Intervention: 60-90 mg amitriptylinoxide (AO)
Number of subjects: 197

Group type: COMPARATOR
Intervention: 50-75 mg amitriptyline (AM)
Number of subjects: 197

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 197
Study: 3123092

Group type: EXPERIMENTAL
Intervention: O-desmethyl encainide (ODE) infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3-methoxy-O-desmethyl encainide (3MODE) infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 9

Group type: COMPARATOR
Intervention: Withdrawal of encainide therapy
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: ODE infusion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 3MODE infusion
Number of subjects: 9
Study: 31561322

Group type: EXPERIMENTAL
Intervention: Ankylosing spondylitis group (AS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (non-AS)
Number of subjects: 30
Study: 31976311

Group type: EXPERIMENTAL
Intervention: FMT
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: FMT-L
Number of subjects: 21
Study: 29066126

Group type: EXPERIMENTAL
Intervention: TRO‐CTA at 100kVp using SAFIRE
Number of subjects: 147

Group type: COMPARATOR
Intervention: TRO‐CTA at 120kVp using FBP
Number of subjects: 147
Study: 26212849

Group type: EXPERIMENTAL
Intervention: Diclofenac
Number of subjects: 104

Group type: COMPARATOR
Intervention: Paracetamol
Number of subjects: 104
Study: 23042922

Group type: EXPERIMENTAL
Intervention: Single-dose gadobenate dimeglumine
Number of subjects: 46

Group type: COMPARATOR
Intervention: Double-dose gadopentetate dimeglumine
Number of subjects: 46
Study: 21796674

Group type: EXPERIMENTAL
Intervention: Positive character evidence for Black defendants
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Negative character evidence for White defendants
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Character evidence inconsistent with racial stereotypes
Number of subjects: 206

Group type: COMPARATOR
Intervention: Race of the character witness
Number of subjects: 206
Study: 19815913

Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg once daily for 14 days)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Comparator (doxycycline 100 mg twice daily + metronidazole 400 mg three times daily for 14 days + single 500 mg ciprofloxacin dose)
Number of subjects: 434

Group type: COMPARATOR
Intervention: Comparator (doxycycline + metronidazole + ciprofloxacin)
Number of subjects: 434
Study: 16500319

Group type: EXPERIMENTAL
Intervention: Detailed blastocyst grading system
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard blastocyst grading system
Number of subjects: 0
Study: 15522045

Group type: EXPERIMENTAL
Intervention: Heart rate variability measures using three commercially available analysers under three conditions: lying supine, standing, lying supine with controlled breathing
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Heart rate variability measures using three commercially available analysers
Number of subjects: 29
Study: 12602538

Group type: EXPERIMENTAL
Intervention: Atorvastatin (T2DA)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (T2Dp)
Number of subjects: 25
Study: 11077317

Group type: EXPERIMENTAL
Intervention: ppWhipple
Number of subjects: 77

Group type: COMPARATOR
Intervention: cWhipple
Number of subjects: 77

Group type: COMPARATOR
Intervention: cWhipple and ppWhipple
Number of subjects: 77
Study: 8813038

Group type: COMPARATOR
Intervention: Zidovudine alone (600 mg)
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine (600 mg + 400 mg)
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine (600 mg + 2.25 mg)
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Didanosine alone (400 mg)
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Zidovudine plus didanosine
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Zidovudine plus zalcitabine
Number of subjects: 2467

Group type: EXPERIMENTAL
Intervention: Didanosine alone
Number of subjects: 2467
Study: 1363986

Group type: EXPERIMENTAL
Intervention: Sulfasalazine, daily dosage of 2 g
Number of subjects: 150
Study: 2861846

Group type: EXPERIMENTAL
Intervention: Desensitization
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 3591726

Group type: EXPERIMENTAL
Intervention: Vitamin A capsule (200,000 IU)
Number of subjects: 19396

Group type: EXPERIMENTAL
Intervention: Nonrecipients
Number of subjects: 19396

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 19396
Study: 30239495

Group type: EXPERIMENTAL
Intervention: 6-min walk test (6MWT)
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: UNCCRI treadmill protocol
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Correlation between UNCCRI treadmill protocol and 6MWT
Number of subjects: 187
Study: 28751299

Group type: EXPERIMENTAL
Intervention: E‐health4Uth Healthy Toddler intervention (Web‐based personalized advice and face-to-face counseling during well-child visits)
Number of subjects: 2102

Group type: EXPERIMENTAL
Intervention: E‐health4Uth Healthy Toddler intervention
Number of subjects: 2102

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2102
Study: 25850817

Group type: EXPERIMENTAL
Intervention: Anteroposterior view
Number of subjects: 201

Group type: COMPARATOR
Intervention: Oblique view
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Both groups (where intravascular injections did not occur)
Number of subjects: 201
Study: 23122889

Group type: EXPERIMENTAL
Intervention: Definite ACS
Number of subjects: 16618

Group type: COMPARATOR
Intervention: Possible ACS
Number of subjects: 16618
Study: 21810938

Group type: EXPERIMENTAL
Intervention: Prilocaine 0.1%
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Prilocaine 0.2%
Number of subjects: 90
Study: 19542686

Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (education)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Low socioeconomic status (income)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: History of hypertension
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: History of diabetes
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Regular intake of folk remedies or over-the-counter Chinese herbs
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Regular intake of multivitamin supplement 5 years before diagnosis
Number of subjects: 200
Study: 16410483

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (dalteparin; 100 IU/kg BID)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Aspirin (160 mg per day)
Number of subjects: 431
Study: 15052247

Group type: EXPERIMENTAL
Intervention: 2-dimensional gated SPECT analysis (SPECTEF)
Number of subjects: 136

Group type: COMPARATOR
Intervention: 3-dimensional QGS
Number of subjects: 136

Group type: COMPARATOR
Intervention: 3-dimensional p-FAST
Number of subjects: 136
Study: 11314826

Group type: EXPERIMENTAL
Intervention: 2.0 grams of MgSO4
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 9440362

Group type: EXPERIMENTAL
Intervention: Maximal onset principle (e.g., MAR-KET)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stress principle (e.g., MARK-ET)
Number of subjects: 0
Study: 7943523

Group type: EXPERIMENTAL
Intervention: Clinical examination by orthopaedic surgeons
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clinical examination for detecting posterior cruciate ligament tear
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Clinical examination for grade II and III posterior laxity
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Agreement on the grade of posterior cruciate ligament tear
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Posterior drawer test
Number of subjects: 39
Study: 3065687

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b at 4 x 10(6) U/m2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b at 2 x 10(6) U/m2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b at 1 x 10(6) U/m2
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b at 1 x 10(6) U twice a week (maintenance therapy)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: IFN alpha‐2b at 2 x 10(6) U once weekly (maintenance therapy)
Number of subjects: 34
Study: 31887617

Group type: EXPERIMENTAL
Intervention: Pomegranate juice and tablets
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo-matching juice and tablets
Number of subjects: 171
Study: 31192928

Group type: EXPERIMENTAL
Intervention: Comprehensive nursing intervention
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine nursing
Number of subjects: 300
Study: 29178917

Group type: EXPERIMENTAL
Intervention: Surface electromyography (EMG)‐triggered electrical stimulation for eight weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 80
Study: 25186211

Group type: EXPERIMENTAL
Intervention: Testimony of a breast cancer survivor (TE group)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Content-equivalent message composed of expert recommendations (RE group)
Number of subjects: 158

Group type: COMPARATOR
Intervention: No message (control group)
Number of subjects: 158
Study: 23457383

Group type: EXPERIMENTAL
Intervention: Tocilizumab (TCZ)
Number of subjects: 4211
Study: 21198431

Group type: EXPERIMENTAL
Intervention: Lopinavir/ritonavir (LPV/r) monotherapy
Number of subjects: 136

Group type: COMPARATOR
Intervention: Lopinavir/ritonavir (LPV/r) + zidovudine (ZDV) + lamivudine (3TC) triple therapy
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 136
Study: 19399311

Group type: EXPERIMENTAL
Intervention: Condom use at first sexual intercourse
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Delay in sexual debut
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Condom use at first sex
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: General condom use ('most or all the time')
Number of subjects: 214
Study: 16796137

Group type: EXPERIMENTAL
Intervention: Controlled mild hypothermia
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 89
Study: 12763982

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg (group A)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Helicobacter pylori test and treat (group B)
Number of subjects: 219
Study: 11785865

Group type: EXPERIMENTAL
Intervention: Medication trolley at the patient's bedside
Number of subjects: 340

Group type: COMPARATOR
Intervention: Ward bay workstation outside the patients' rooms
Number of subjects: 340
Study: 9220221

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 299

Group type: COMPARATOR
Intervention: Lovastatin
Number of subjects: 299

Group type: COMPARATOR
Intervention: Pravastatin
Number of subjects: 299

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 299
Study: 8421977

Group type: EXPERIMENTAL
Intervention: Presence of epsilon 4 allele
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Presence of epsilon 2 allele
Number of subjects: 619

Group type: EXPERIMENTAL
Intervention: Changes in LDL cholesterol over time
Number of subjects: 619
Study: 3798631

Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg X 3)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Estramustine (280 mg X 2)
Number of subjects: 30
Study: 31162372

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial (CPAP with 10 cmH2O pressure support, 5 cmH2O PEEP, FiO2 ≤ 0.5 for 2 hours)
Number of subjects: 110

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing trial
Number of subjects: 110

Group type: COMPARATOR
Intervention: Control group (ventilator weaning according to clinical judgment)
Number of subjects: 110
Study: 28855115

Group type: EXPERIMENTAL
Intervention: Catheter Ablation (CA)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Medical Rate Control (MRC)
Number of subjects: 68
Study: 26017126

Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia at 33°C initiated within 3 hours of injury and continued for at least 72 hours
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard normothermic management
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Prophylactic hypothermia
Number of subjects: 500
Study: 23747076

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21357280

Group type: EXPERIMENTAL
Intervention: Standardized diet to gain ≈4 kg over 8 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Weight-maintainer control
Number of subjects: 36
Study: 19522391

Group type: EXPERIMENTAL
Intervention: Liqi decoction (oral for 2 to 3 days)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (fasting and enema, gastrointestinal decompression)
Number of subjects: 75
Study: 16769828

Group type: EXPERIMENTAL
Intervention: High-risk prethreshold ROP
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-risk prethreshold ROP
Number of subjects: 0